Healthcare use by varied highly active antiretroviral therapy (HAART) strata
- 1 March 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (4) , 621-630
- https://doi.org/10.1097/00002030-200403050-00006
Abstract
Prior reports have found a temporal association between the introduction of highly active antiretroviral therapy (HAART) and population rates of health service use among persons living with HIV. Our objective was to explore further the effect of HAART by comparing healthcare use among persons who use HAART and persons who discontinue HAART to that among HAART-naive and HIV-negative persons. Longitudinal analyses of 1485 women with and at-risk for HIV who contributed data to the Women's Interagency HIV Study between April 1997 and March 2000. Compared with HAART-naive women, those using HAART had a higher probability of more than three primary care visits per 6 months [odds ratio (OR), 1.38; 95% confidence interval (CI), 1.16-1.65), a lower probability of more than one emergency room visit per 6 months (OR, 0.75; CI, 0.59-0.95), and a lower probability of more than one hospitalization per 6 months (OR, 0.67; CI, 0.51-0.88). Compared with HAART-naive women, women who had discontinued HAART had a higher frequency of primary care visits (OR, 1.57; CI, 1.26-1.97) but did not demonstrate a significant change in emergency room or hospital use. Modeling of a standardized population HIV-positive women without AIDS indicated hospitalization and emergency room use among HAART users was equivalent to that among HIV-negative women. HIV-positive HAART users (without AIDS) exhibited emergency room and hospitalization use patterns equivalent to those of HIV-negative women. Furthermore, the discontinuation of HAART was associated with a loss of the reduction in hospital use that was achieved with HAART.Keywords
This publication has 30 references indexed in Scilit:
- Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infectionsHepatology, 2002
- Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapyAIDS, 2001
- Metabolic Disorders Among HIV-Infected Patients Treated With Protease Inhibitors: A ReviewJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000
- Hyperlactatemia and Hepatic Abnormalities in 10 Human Immunodeficiency Virus-Infected Patients Receiving Nucleoside Analogue Combination RegimensClinical Infectious Diseases, 2000
- A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndromeAIDS, 2000
- Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus InfectionJAMA, 2000
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitorsAIDS, 1999
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998